Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 10, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares under Share Reward Plan |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £15.9292 per share |
| Transaction Date | August 9, 2018 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of shares by nine senior executives under the Company's Share Reward Plan. Each executive acquired a total of 16 Ordinary Shares (comprising 8 partnership shares and 8 matching shares).
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on strategy, risks, contingencies, or unusual items. It is a regulatory disclosure of specific equity transactions.
Important Facts for Investors
- Insider Activity: Nine senior executives, including CEO Emma Walmsley and CFO Simon Dingemans, acquired shares on August 9, 2018.
- Transaction Volume: Each executive acquired a nominal volume of 16 shares, indicating these were likely vesting events or matching contributions rather than open-market purchases.
- Share Price: The transactions occurred at a price of £15.9292 per share.
- No Financial Data: This filing contains no data regarding GSK's revenue, earnings, or cash flow for the period.